Federal Supply Schedule 36F79720D0239

Award Date 9/15/20
Last Date to Order 9/14/25
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV award is a Federal Supply Schedule (FSS) contract under Schedule 65 IB, which covers Drugs, Pharmaceuticals, and Hematology Related Products. The contract was awarded to HLS Therapeutics Inc., a for-profit manufacturer, on July 1, 2022 by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency of the U.S. federal government. The contract has a ceiling value of $13,848,500.00 and a period of performance through June 30, 2027. It is a multiple award...
The federal contract IDV is a Federal Supply Schedule (FSS) contract awarded by the U.S. Department of Veterans Affairs, Veterans Integrated Service Network 12 (VISN 12), a civilian agency. The contract has a ceiling value of $419,690.00 and a period of performance ending on September 1, 2027. The prime contractor is Altathera Pharmaceuticals LLC, a for-profit limited liability company that manufactures goods. The purpose of this FSS contract is to provide the VA VISN 12 with "Drugs,...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract under Schedule 65 I B Drugs, Pharmaceuticals, & Hematology Related Products. The contract was awarded by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency of the U.S. federal government. The prime contractor is Usantibiotics LLC, a for-profit organization. The contract is an interim agreement with a ceiling value of $25,000.00 and a period of performance through April 1, 2023. The contract does...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract under Schedule 65 I B for Drugs, Pharmaceuticals, & Hematology Related Products. The contracting agency is the Department of Veterans Affairs (VA), specifically the Veterans Integrated Service Network 12 (VISN 12). The prime contractor is Reata Pharmaceuticals, Inc., a for-profit organization. The contract has a ceiling value of $25,000.00 and a period of performance ending on October 23, 2023. It is a multiple...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract, specifically under the Pharmaceuticals and Drugs (FSS-61-IB) master schedule. The contract was awarded to Almirall, LLC, a foreign-owned, for-profit manufacturer of goods. The contract has a ceiling value of $5,500,000.00 and a period of performance through May 15, 2025. The contract is intended to procure drugs, pharmaceuticals, and hematology-related products for the Veterans Integrated Service Network 12 (VISN 12),...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, awarded by the Veterans Integrated Service Network 12 (VISN 12) of the U.S. Department of Veterans Affairs (VA). The prime contractor is Amphastar Pharmaceuticals, Inc., a for-profit manufacturer of pharmaceutical goods. The $58,244,500 multiple award contract has a period of performance through January 14, 2027 and aims to procure a broad range of drug,...
The federal contract IDV award is for a Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs (VA) for "65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS." The prime contractor is Kamada Inc., a foreign-owned for-profit organization. The contract has a ceiling value of $750,000.00 and a period of performance from July 1, 2024 to June 30, 2029. The contract was awarded without any set-asides and is a multiple award. As an FSS contract, it...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract under Schedule 65 IB for Drugs, Pharmaceuticals, and Hematology Related Products. The contracting agency is the Department of Veterans Affairs (VA), specifically Veterans Integrated Service Network 12. The prime contractor is Alpha Cognition USA, Inc., a for-profit manufacturer. The contract has a ceiling value of $25,000.00 and a period of performance through September 30, 2025. It is a multiple award IDV, meaning...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Alvogen, Inc., a for-profit manufacturer of pharmaceutical and healthcare products. The contract, valued at $32,885,990.00, is for the provision of pharmaceuticals, drugs, and hematology-related products (FSS-61-IB) to the VA and other federal agencies. The contract has an ultimate completion date of September 1, 2025 and was originally awarded on April 15, 2017. It is...
The federal contract IDV is a Federal Supply Schedule (FSS) contract awarded by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency, to Tonix Medicines, Inc. The contract has a period of performance from August 1, 2024 to July 31, 2029 and a ceiling value of $250,000.00. The contract is for the procurement of 65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS. As an FSS contract, it allows for the purchase of the awarded products and services by various federal...

The federal contract IDV award is a Federal Supply Schedule (FSS) contract (FSS-61-IB) with the Department of Veterans Affairs' Veterans Integrated Service Network 12 (VISN 12), a civilian agency. The prime contractor is Redhill Biopharma, Inc., a for-profit pharmaceutical manufacturer. The contract has a $225,000 ceiling value and a period of performance from September 15, 2020 to September 14, 2025.

The contract is for the delivery of drugs, pharmaceuticals, and hematology-related products under the Pharmaceuticals and Drugs Federal Supply Schedule. While the provided information does not include the full list of products or pricing, the contract appears to focus on the development and supply of advanced pharmaceutical interventions, with a specific example being a contract with the Department of Health and Human Services for the development of an Ebola virus disease treatment. This suggests the contractor has significant expertise in pharmaceutical research and the ability to deliver specialized, innovative drug therapies to federal agencies.

Generated 5/30/25, 9:45 AM